# Trump Administration ‘Very Anxious’ To Allow Psychedelic Therapy ‘As Quickly As Possible … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/expedited-psychedelics-regulatory-review-2026/ > **Published:** 2026-04-25T01:40:39-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T21:37:07-04:00 > **Clinical Summary:** Explore the expedited psychedelics regulatory review and its impact on psychedelic therapy development and safety monitoring in 2026. --- ✦ New CED Clinical Relevance #8 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyMental HealthResearchSafety Dr. Caplan’s Take “If we’re going to move psychedelics through the regulatory pipeline responsibly, we need the same rigor we apply to any psychiatric medication, regardless of political enthusiasm or timelines, because patients with treatment-resistant depression deserve efficacy data and safety monitoring, not expedited hope.” Clinical Perspective While recent political statements suggest accelerated pathways for psychedelic-assisted therapies, healthcare providers should recognize that regulatory enthusiasm does not replace the need for rigorous clinical evidence and established safety monitoring protocols. The potential for expedited FDA review of psilocybin and MDMA-assisted treatments for conditions like treatment-resistant depression and PTSD reflects genuine clinical interest, but rapid approval timelines carry inherent risks of insufficient long-term safety data, inadequate clinician training standards, and premature integration into routine practice before optimal patient selection criteria are defined. Providers should remain attentive to emerging [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) and regulatory developments while maintaining appropriate skepticism toward politicized drug policy, recognizing that administrative pressure can sometimes outpace scientific validation. Until robust evidence establishes efficacy, safety profiles, and training requirements comparable to other psychiatric interventions, clinicians should continue referring interested patients to legitimate [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) rather than seeking off-label access. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20Administration%20%E2%80%98Very%20Anxious%E2%80%99%20To%20Allow%20Psychedelic%20Therapy%20%E2%80%98As%20Quickly%20As%20Possible%20%E2%80%A6%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Ftrump-administration-very-anxious-to-allow-psychedelic-therapy-as-quickly-as-possible%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ftrump-administration-very-anxious-to-allow-psychedelic-therapy-as-quickly-as-possible%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20Administration%20%E2%80%98Very%20Anxious%E2%80%99%20To%20Allow%20Psychedelic%20Therapy%20%E2%80%98As%20Quickly%20As%20Possible%20%E2%80%A6%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Ftrump-administration-very-anxious-to-allow-psychedelic-therapy-as-quickly-as-possible%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know](https://cedclinic.com/tenet-healthcare-revvity-avantor-azenta-and-elanco-shares-plummet-what-you-need-to-know/) An overview of recent stock market movements affecting healthcare and biotech companies relevant to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and regulatory environments. [Read More](https://cedclinic.com/tenet-healthcare-revvity-avantor-azenta-and-elanco-shares-plummet-what-you-need-to-know/) [Bemidji Chamber Ambassadors Welcome Coconut Cannabis](https://cedclinic.com/bemidji-chamber-ambassadors-welcome-coconut-cannabis/) Insights into cannabis industry developments and community engagement that influence clinical and regulatory landscapes. [Discover More](https://cedclinic.com/bemidji-chamber-ambassadors-welcome-coconut-cannabis/) [The Best CBD for Immune Support and Daily Resilience in 2026 | stupidDOPE | Est. 2008](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) A review of top [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) supporting immune health, relevant to ongoing discussions about cannabinoid therapies and regulatory considerations. [Explore Now](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).